Well, good morning, everybody, and thank you once again for joining us for the 46th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team, and it's a great pleasure to moderate ...

This year’s Rare Disease Day event Feb. 27 at the Jacobs School of Medicine and Biomedical Sciences focused on updates in research and diagnostics, and advancements in treatment.

SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.

Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and ...

Learn how LEMS affects more than just muscles and explore tips for managing hidden symptoms like dry mouth, GI issues, and blurred vision while advocating for comprehensive care.

Argenx Se ( (ARGX)) has provided an update. On March 6, 2026, Argenx announced it will present extensive new data on VYVGART and its neurology pipeline at the American Academy of Neurology Annual ...

A decade ago, Doug Upton was the picture of strength as a U.S. Marine Corps officer stationed in Jordan. But in 2016, subtle warning signs emerged, indicating something wasn’t quite right. “My legs ...

Eighteen months ago, artist Logan Kirkpatrick was invited to exhibit her work at Cooley Dickinson Hospital. Little did she know at the time, though, that she’d soon end up a patient at the Northampton ...

Adjusted EBITDA -- $231 million, up 40% year over year, demonstrating significant operating leverage. Adjusted net income -- $160.8 million, a 35% year-over-year increase, confirming margin expansion ...

The first phase of the Skimmer?Heritage integration enables Skimmer customers to sync Heritage product data directly into their Skimmer accounts. This live connection ensures product information ...

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...

This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal ...